You are here: Welcome to the MPKB » Welcome to the MPKB » Resources for physicians » Physicians' concerns about the Marshall Protocol
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:physicians:concerns [02.09.2019] – [Numerical improvements update] sallieqhome:physicians:concerns [05.09.2019] – [Numerical improvements update] sallieq
Line 5: Line 5:
 ===== Concerns about lack of clinical evidence ===== ===== Concerns about lack of clinical evidence =====
  
-  - **"There are no well-controlled studies to support the use of the Marshall Protocol for a given indication."** This statement is accurate. At this point, patients and physicians who choose to use and administer the MP do so based on the following evidence:+  - **"There are no well-controlled studies to support the use of the Marshall Protocol for a given indication."** This statement is accurate. As of 2012, patients and physicians who choose to use and administer the MP do so based on the following evidence:
     * a [[home:publications:proal_molecular_2011|2011 case series of MP patients]] appearing in the (Nature Publishing Group) journal //Clinical & molecular immunology//     * a [[home:publications:proal_molecular_2011|2011 case series of MP patients]] appearing in the (Nature Publishing Group) journal //Clinical & molecular immunology//
     * a [[home:publications:mp2008_survey|2008 retrospective survey]] of 100 MP patients with autoimmune diagnoses     * a [[home:publications:mp2008_survey|2008 retrospective survey]] of 100 MP patients with autoimmune diagnoses
Line 16: Line 16:
 For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment: For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment:
   * evidence for the efficacy of MP versus other available treatment options(({{pubmed>long:19050187}}))   * evidence for the efficacy of MP versus other available treatment options(({{pubmed>long:19050187}}))
 +  * more recent material on patient response, see below update
   * patients' expressed preferences and values(({{pubmed>long:19050187}}))   * patients' expressed preferences and values(({{pubmed>long:19050187}}))
   * additional benefits of Olmesartan [[https://mpkb.org/home/protocol/olmesartan#other_benefits_of_olmesartan_in_patients_-_recent_studies|other researched benefits]]   * additional benefits of Olmesartan [[https://mpkb.org/home/protocol/olmesartan#other_benefits_of_olmesartan_in_patients_-_recent_studies|other researched benefits]]
Line 24: Line 25:
 <html></p></div></html> <html></p></div></html>
  
-===== Numerical improvements update =====+===== Recorded success rates  =====
  
 <blockquote>//DJ posted// :- During the summer of 2013 I looked at 2,000 records of people using the Marshall Protocol.</blockquote>  <blockquote>//DJ posted// :- During the summer of 2013 I looked at 2,000 records of people using the Marshall Protocol.</blockquote> 
home/physicians/concerns.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.